BIOCODEX

The 2024 Dravet Syndrome Global Clinical Trials Review is now available on ResearchAndMarkets.com, offering insights into clinical trials worldwide, including trial numbers, enrollment, and prominent drugs in progress.

The "Hyperoxaluria - Pipeline Insight, 2024" report details over 9 companies and 10+ drugs in development for Hyperoxaluria, covering clinical and nonclinical stages. It highlights therapeutic assessments, emerging drugs like Oxabact and SYNB8802, and key players such as OxThera and Synlogic. The report also explores R&D challenges, collaborations, and recent trends in treatment approaches.

MaaT Pharma announces a €18 million offering to fund Microbiome Ecosystem Therapies development, including Phase 3 trials for MaaT013 and MaaT033. The offering includes new shares at €8 each, with €14.3m committed by historical shareholders. The company aims to extend its cash runway into early 2025.

MaaT Pharma secured an additional €7.35 million in Series B financing, totaling €25.35 million, to advance its microbiome restoration biotherapeutics platform. The funding supports the development of next-generation microbiome ecosystem therapeutics, including MaaT013 and MaaT033 for GvHD and cancer treatment, and expands the pipeline towards solid tumors.